| |
| |
| Exchange: |
Nasdaq National Market |
| Security
Type: |
Common |
| Shares
Out: |
381,510,000 |
| Market
Cap: |
169.20(M) |
| Last
Volume: |
4,513,016 |
Avg
Vol: |
4,500,422 |
| 52
Week Range: |
$0.4435 - $2.04 |
|
| Level
I Sector: |
Health Care |
| Level
II Sector: |
Drugs |
| Level
III Sector: |
Biotechnology |
|
Member Indexes:
|
| |
NASDAQ BIOTECHNOLOGY |
|
NASDAQ COMPOSITE |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Agenus is a clinical-stage immuno-oncology (I-O) company engaged in the development of a pipeline of immune checkpoint antibodies, adoptive cell therapies and neoantigen cancer vaccines, to fight cancer and infections. Co.'s antibody candidates are balstilimab (an anti-PD-1 antibody) and zalifrelimab (an anti-CTLA-4 antibody), which are in Phase 2 trials as both a monotherapy (balstilimab) and combination therapy (balstilimab/zalifrelimab) for treatment of patients with second-line cervical cancer. Co. is also developing an anti-CTLA-4 antibody, botensilimab (also known as AGEN1181), which is designed to improve the magnitude of responses to first-generation anti-CTLA-4 molecules.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
500,000 |
525,000 |
525,000 |
525,000 |
| Total Buy Value |
$324,050 |
$343,050 |
$343,050 |
$343,050 |
| Total People Bought |
1 |
2 |
2 |
2 |
| Total Buy Transactions |
1 |
2 |
2 |
2 |
| Total Shares Sold |
0 |
0 |
0 |
0 |
| Total Sell Value |
$0 |
$0 |
$0 |
$0 |
| Total People Sold |
0 |
0 |
0 |
0 |
| Total Sell Transactions |
0 |
0 |
0 |
0 |
| End Date |
2024-02-01 |
2023-10-31 |
2023-05-02 |
2022-05-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Valentine Karen |
Chief Legal Officer |
• – – |
2017-04-19 |
4 |
A |
$3.39 |
$84,147 |
D/D |
24,822 |
93,110 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2017-04-19 |
4 |
A |
$3.39 |
$243,958 |
D/D |
71,964 |
1,490,441 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• • – |
2017-04-12 |
4 |
B |
$3.29 |
$97,055 |
D/D |
29,456 |
1,418,477 |
2.81 |
- |
|
| Armen Garo H |
Chairman & CEO |
• • – |
2017-04-10 |
4 |
B |
$3.37 |
$237,465 |
D/D |
70,544 |
1,389,021 |
2.81 |
- |
|
| Incyte Corp |
10% Owner |
– – • |
2017-02-14 |
4 |
B |
$6.00 |
$60,000,000 |
D/D |
10,000,000 |
17,763,968 |
2.45 |
- |
|
| Baysal Ozer |
Chief Business Officer |
• – – |
2017-01-03 |
4 |
A |
$4.16 |
$26,000 |
D/D |
6,250 |
39,883 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2016-12-22 |
4 |
D |
$4.06 |
$618,764 |
D/D |
(152,405) |
1,318,477 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2016-12-21 |
4 |
D |
$4.19 |
$326,824 |
D/D |
(78,001) |
1,470,882 |
|
- |
|
| Wiinberg Ulf |
Director |
– • – |
2016-09-06 |
4 |
B |
$6.29 |
$188,700 |
D/D |
30,000 |
30,000 |
2.39 |
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2016-06-29 |
4 |
A |
$3.63 |
$553,230 |
D/D |
152,405 |
1,548,883 |
|
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2016-05-09 |
4 |
B |
$3.28 |
$163,935 |
D/D |
50,000 |
1,396,026 |
2.74 |
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2016-05-06 |
4/A |
B |
$3.08 |
$153,960 |
D/D |
50,000 |
1,346,026 |
2.74 |
- |
|
| Armen Garo H |
Chairman & CEO |
• – – |
2016-05-05 |
4 |
B |
$3.08 |
$153,960 |
D/D |
50,000 |
1,346,026 |
2.74 |
- |
|
| Baysal Ozer |
Chief Business Officer |
• – – |
2016-05-05 |
4 |
B |
$3.10 |
$6,975 |
D/D |
2,250 |
33,538 |
2.74 |
- |
|
| Stein Robert Benjamin |
President R&D |
• – – |
2016-04-26 |
4/A |
|
$4.15 |
$51,414 |
D/D |
12,389 |
20,986 |
|
- |
|
| Stein Robert Benjamin |
President R&D |
• – – |
2016-04-26 |
4/A |
A |
$4.15 |
$138,506 |
D/D |
33,375 |
33,375 |
|
- |
|
| Ballantyne Charles Evan |
Chief Financial Officer |
• – – |
2016-04-26 |
4/A |
D |
$4.15 |
$29,494 |
D/D |
(7,107) |
24,795 |
|
- |
|
| Ballantyne Charles Evan |
Chief Financial Officer |
• – – |
2016-04-26 |
4/A |
A |
$4.15 |
$90,893 |
D/D |
21,902 |
31,902 |
|
- |
|
| Valentine Karen |
Chief Legal Officer |
• – – |
2016-04-26 |
4/A |
|
$4.15 |
$33,482 |
D/D |
8,068 |
68,288 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• – – |
2016-04-26 |
4/A |
D |
$4.15 |
$110,863 |
D/D |
(26,714) |
1,396,478 |
|
- |
|
| Armen Garo H |
Chairman and CEO |
• – – |
2016-04-26 |
4/A |
A |
$4.15 |
$298,651 |
D/D |
71,964 |
1,423,192 |
|
- |
|
| Valentine Karen |
Chief Legal Officer |
• – – |
2016-04-26 |
4/A |
D |
$4.15 |
$33,482 |
D/D |
(8,068) |
68,288 |
|
- |
|
| Valentine Karen |
Chief Legal Officer |
• – – |
2016-04-26 |
4/A |
A |
$4.15 |
$103,011 |
D/D |
24,822 |
76,356 |
|
- |
|
| Klaskin Christine M |
VP Finance |
• – – |
2016-04-26 |
4/A |
D |
$4.15 |
$14,745 |
D/D |
(3,553) |
52,816 |
|
- |
|
| Klaskin Christine M |
VP Finance |
• – – |
2016-04-26 |
4/A |
A |
$4.15 |
$43,280 |
D/D |
10,429 |
55,369 |
|
- |
|
186 Records found
|
|
Page 6 of 8 |
|
|
